Single center experience with alpelisib-fulvestrant in heavily pretreated women with HR(+), HER-2 (-) metastatic breast cancer.

被引：0
|
作者：
Tryfonopoulos, Dimitrios
Tzouda, Vasiliki
Zouki, Dionysia
Kyriakidou, Athina
Sarris, Evangelos
Grivas, Anastasios
Gouveris, Panagiotis
Papaxoinis, George
Demiri, Stamatina G.
机构：
[1] St Savas AntiCanc Hosp, Athens, Greece
[2] Hosp Agios Savvas, Athens, Greece
[3] Agios Savvas Canc Hosp, Athens, Greece
[4] Agios Savvas Anticanc Hosp, Athens, Greece
[5] Agios Savvas Anticanc Hosp, Athens, CT, Greece
[6] Agios Savvas Anticanc Hosp, Dept Med Oncol 2, Athens, Greece
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13034
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC).
    Salvador, Javier
    Ruiz Borrego, Manuel
    Valero, Maria
    Bayo, Juan L.
    De La Cruz-Merino, Luis
    Carabantes, FRancisco
    Rodriguez de la Borbolla, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] Abemaciclib for the Treatment of HR+HER2-Metastatic Breast Cancer: An Institutional Experience
    Matos, Erika
    Cankar, Kaja
    Rezun, Neza
    Dejanovic, Katja
    Ovcaricek, Tanja
    CANCERS, 2024, 16 (10)
  • [43] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
  • [44] COMPARATIVE EFFECTIVENESS OF EVEROLIMUS VS. FULVESTRANT MONOTHERAPY AMONG POSTMENOPAUSAL WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER
    Lin, P. L.
    Hao, Y.
    Xie, J.
    Li, N.
    Ohashi, E.
    Koo, V
    Wu, E. Q.
    VALUE IN HEALTH, 2015, 18 (03) : A192 - A192
  • [45] Fulvestrant Monotherapy in Metastatic Breast Cancer (MBC): a Single Centre Experience
    Okonji, D.
    Redana, S.
    Iyer, R.
    Mohammed, K.
    Ring, A.
    Johnston, S.
    CLINICAL ONCOLOGY, 2017, 29 (06) : E101 - E102
  • [46] Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.
    Engel-Nitz, Nicole M.
    Becker, Laura
    Gerdes, Randall
    Hao, Yanni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] Fulvestrant in heavily pretreated ER-positive postmenopausal metastatic breast cancer patients: A phase II study
    Ratti, R.
    Coccorullo, Z.
    Guarneri, D.
    Addamo, G.
    Colloca, G.
    Venturino, A.
    Campora, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [48] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer at a Single Cancer Center
    Knudsen, Erik S.
    Schultz, Emily
    Hamilton, Deanna
    Attwood, Kris
    Edge, Stephen
    O'Connor, Tracey
    Levine, Ellis
    Witkiewicz, Agnieszka K.
    ONCOLOGIST, 2022, 27 (08): : 646 - 654
  • [49] Real-world experience with CDK4/6 inhibitors for metastatic HR+/HER2-breast cancer at a single cancer center
    Milovic-Kovacevic, M.
    Bobic, S.
    Karaferic, A.
    Pavlovic, L.
    Matovic, M.
    Poparic-Bandjur, B.
    BREAST, 2023, 68 : S115 - S115
  • [50] Nab-paclitaxel plus bevacizumab in heavily pretreated HER2-negative metastatic breast cancer
    Miano, S. T.
    Rossi, G.
    Marsili, S.
    Petrioli, R.
    Pascucci, A.
    Francini, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 22 - 23
12345